2026-01-04 - Analysis Report
Okay, here's a comprehensive report on Johnson & Johnson (JNJ) based on the provided data.

**1. Return Rate Comparison & Analysis**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a diversified healthcare company focused on pharmaceuticals, medical devices, and consumer health products.
*   **Cumulative Return (JNJ):** 52.36%
*   **Cumulative Return (VOO - S&P 500):** 91.00%
*   **Divergence:**
    *   Current: -38.6
    *   Relative Divergence: 31.4
    *   (Max: 13.6, Min: -62.5)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The current divergence of -38.6 indicates a substantial difference in cumulative returns. The relative divergence of 31.4 suggests that the current divergence is relatively low compared to its historical range, suggesting that underperformance compared to the S\&P 500 has been worse at times, though it is still significantly negative.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2016-2018  | 6.0%   | 16.8% | 3.0%   | 0.7   | 310.9  |
| 2017-2019  | 18.0%  | 16.8% | 1.0%   | 0.7   | 351.4  |
| 2018-2020  | 19.0%  | 16.8% | -2.0%  | 0.7   | 379.2  |
| 2019-2021  | 32.0%  | 10.7% | -12.0% | 0.6   | 412.2  |
| 2020-2022  | 8.0%   | 13.8% | 10.0%  | 0.5   | 425.6  |
| 2021-2023  | -18.0% | 13.8% | -19.0% | 0.3   | 377.6  |
| 2022-2024  | -30.0% | 13.8% | -50.0% | 0.2   | 348.4  |
| 2023-2025  | 30.0%  | 13.8% | -32.0% | 0.1   | 498.6  |

*   **CAGR (Compound Annual Growth Rate):** Shows the average annual growth rate over the specified periods.  Fluctuating, but generally positive until recently.
*   **MDD (Maximum Drawdown):** Represents the largest peak-to-trough decline during the period. Relatively stable MDD indicates consistent downside risk.
*   **Alpha:**  Measures the excess return compared to the benchmark (market).  Negative alpha in recent periods suggests underperformance relative to the market. Alpha has trended negative in more recent years (especially 2021-2025).
*   **Beta:** Measures the stock's volatility relative to the market. Beta consistently below 1 indicates lower volatility than the market. Beta has trended downward over time.
*   **Cap(B):** Market Capitalization in Billions. Fluctuating, and at its highest recently.

**2. Recent Stock Price Fluctuations**

*   **Close:** 207.35
*   **Last-market:**  `{'price': 207.35, 'previousClose': 206.95, 'change': 0.19}`
*   **5-day SMA:** 207.28
*   **20-day SMA:** 206.994
*   **60-day SMA:** 198.7602

**Analysis:** The current price is above all the SMAs and there is a bullish trend based on this information. The 5-day and 20-day SMAs are very close, suggesting short-term price stability. The price being significantly above the 60-day SMA indicates a recent upward trend. The `change` of 0.19 suggests a modest positive movement in the last trading session.

**3. RSI, PPO & Market Risk Indicator Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 43.29
*   **PPO:** -0.33
*   **Hybrid Signal:** `cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.70)`
*   **Recent (20 days) relative divergence change:** 2.6 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -52.2%

**Analysis:**

*   **MRI:** The MRI of 0.8 suggests a medium level of investment risk, supporting a moderate investment approach.
*   **RSI:** The RSI of 43.29 is below 50, indicating that the stock is not overbought, but it's also not in deeply oversold territory.
*   **PPO:** The negative PPO (-0.33) suggests that the short-term moving average is below the long-term moving average, potentially indicating a downtrend, but it is not largely negative, suggesting that the trend is relatively neutral.
*   **Hybrid Signal:** The hybrid signal suggests using caution and buying a limited number of shares (2) with 80% of available cash.
*   **Divergence Change:** The recent increase in relative divergence suggests a short-term upward trend.
*   **Expected Return:** The extremely negative expected return (-52.2%) is a significant concern.  It suggests a very pessimistic outlook for long-term investment in JNJ compared to the S&P 500 from this point.

**4. Recent News & Significant Events**

*   **[2025-12-30] More Upside For JNJ Stock In 2026? - Forbes:** Suggests potential optimism for the future.
*   **[2026-01-03] Johnson & Johnson stock today: JNJ’s $1.30 dividend sets key dates:** Focuses on dividend aspects, signaling stability for investors.
*   **[2025-12-19] Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs - Yahoo Finance:** Highlights positive developments in pharmaceuticals (cancer drugs).
*   **[2026-01-02] Johnson & Johnson declares $1.30 per share dividend for Q1 2026 - Investing.com:** Reinforces dividend reliability.
*   **[2026-01-04] Delta Investment Management LLC Acquires 5,284 Shares of Johnson & Johnson $JNJ - MarketBeat:** Indicates institutional investor confidence.
*   **[2025-12-12] These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same? - The Motley Fool:** Signals possible buy opportunities based on institutional activity.

**Analysis:** The news headlines present a mixed picture.  There are positive signals related to dividends, potential upside, cancer drug developments, and institutional investment.  This positive sentiment contrasts sharply with the negative expected return.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.16)
*   **Opinions:** 24
*   **Target Price:** Avg: 210.13 / High: 240.00 / Low: 155.00
*   **Recent Rating Changes:** Not Available

**Analysis:** The analyst consensus is "Buy," with an average target price slightly above the current price, suggesting a moderate upside potential. However, the wide range between high and low target prices indicates some uncertainty among analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$ |

**Analysis:** Revenue appears to be relatively stable. EPS is fluctuating, but in the previous three quarters, the EPS has been higher than the past two years.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $23.99B   | 69.56%         |
| 2025-06-30   | $23.74B   | 67.87%         |
| 2025-03-31   | $21.89B   | 66.40%         |
| 2024-12-31   | $22.52B   | 68.35%         |
| 2024-09-30   | $22.47B   | 69.01%         |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $79.28B   | 6.50%   |
| 2025-06-30   | $78.47B   | 7.06%   |
| 2025-03-31   | $78.11B   | 14.08%  |
| 2024-12-31   | $71.49B   | 4.80%   |
| 2024-09-30   | $70.16B   | 3.84%   |

**Analysis:**

*   **Revenue:** Revenue is relatively stable across the past five quarters.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
*   **Equity:** Equity has been steadily increasing.
*   **ROE (Return on Equity):** ROE fluctuates, with a significant spike in 2025-03-31 and then trending downward in the past two quarters. The recent quarters appear to be positive signals.

**7. Comprehensive Analysis**

Johnson & Johnson presents a mixed investment picture.

*   **Negative Signals:** The stock has significantly underperformed the S&P 500.  The most alarming is the extremely negative expected return (-52.2%), signaling a pessimistic outlook compared to the market. Recent Alpha values have also been trending negative.
*   **Positive Signals:** The analyst consensus is a "Buy." Recent news headlines indicate positive developments in cancer drugs, dividend reliability, and institutional investment. Profit margins are high, and recent SMA, EPS and ROE values are showing a positive trend.
*   **Mixed Signals:** The MRI suggests a medium level of risk. The hybrid signal advises cautious buying.

**Recommendation:**

Given the very negative expected return and underperformance against the S&P 500, a cautious approach is warranted. While some positive signals exist, the negative outlook should not be ignored. Further investigation into the factors driving the negative expected return is necessary before making a significant investment decision. The hybrid signal's recommendation to buy a small number of shares with caution seems appropriate.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.